Genotypes of associated polymorphisms and adjusted odds ratios for associations between gene variants and EULAR anti-TNF treatment response.

<p>Logistic regression, adjusted (Adj.) for sex, age, HAQ, CRP, DMARD at baseline, IgM RF status (seropositive/seronegative). CI: confidence interval, Freq.: Frequency, OR: odds ratio, EULAR: European League Against Rheumatism, P-value: *<0.05, **<0.01.</p

Polymorphisms’ effect on anti−/pro-inflammatory signal and chance of good anti-TNF response (EULAR good/moderate or ACR50).

<p>EULAR (*): European League Against Rheumatism ACR50 (#): American College of Rheumatology response criterion (50% improvement).</p

Adjusted odds ratio (OR) for associations between gene variants and ACR50 and relDAS28 response to anti-TNF treatment.

<p>Adj. OR: adjusted odds ratio for ACR50 and coefficient (Coeff.) for relative change in DAS28 (relDAS28). Adjusted for gender, age, HAQ-, DMARD at baseline, CRP, IgM RF status (seropositive/seronegative). Freq.: frequency.</p

Odds ratio (OR) for association between <i>NLRP3</i> (rs4612666) variant allele and EULAR good/moderate response (log scale, 95% confidence interval).

<p>Patients stratified on diagnose (seropositive-/seronegative RA) or smoking status. Smoking as independent predictor of EULAR good/moderate response: OR = 1.018, p = 0.941.</p

Aggregate genetic risk score.

<p>Weighted odds ratio (OR) for seropositive RA patients’ risk of EULAR non-response according to the number of associated polymorphisms, relative to patients with zero associated polymorphisms. Number of patients in bars. NS: not significant. P-value: **<0.01, ***<0.001.</p

Baseline clinical and demographic characteristics.

<p>SD: standard deviation, DMARD: disease modifying anti-rheumatic drugs, VAS: visual analogue scale, TJC: tender joint count, SJC: swollen joint count, HAQ: health assessment score, CRP: C-reactive protein, DAS28: disease activity score (28-joints), EULAR: European League Against Rheumatism, ACR50: American College of Rheumatology, 50% improvement, RelDAS28: relative change in DAS28.</p

Description of the study participants.

<p>Description of the study participants.</p

The biologic effect of the studied single nucleotide polymorphism (SNP) and odds ratios (OR) for polymorphisms which have been shown to be associated with risk of Crohn's disease (CD), ulcerative colitis (UC) or inflammatory bowel disease (IBD) in previous studies and in this study.

A<p>Crude (unadjusted).</p>B<p>Adjusted for age, gender and smoking status.</p>C<p>Function examined by flow cytometry.</p>D<p>Function examined by luciferase reporter assay.</p>E<p>Function examined by enzyme-linked immunosorbent assay (ELISA).</p>F<p>Function examined by reverse transcriptase PCR (RT-PCR).</p>G<p>Function examined by electrophoretic mobility shift assay (EMSA).</p><p>ND: not determined.</p

Sixteen functional single nucleotide polymorphisms (SNPs) in 13 genes involved in regulation of inflammation were found to be associated with susceptability of severe Crohn's disease (CD), ulcerative colitis (UC) or inflammatory bowel diseases (IBD).

<p>Eleven of the SNPs have not previously been reported as susceptability polymorphisms of CD, UC or IBD (<i>TLR2</i> (rs4696480 and rs1816702), <i>TLR4</i> (rs1554973 and rs12377632), <i>TLR9</i> (rs187084 and rs352139), <i>LY96</i> (rs11465996), <i>NFKBIA</i> (rs696), <i>TNFRSF1A</i> (rs4149570), <i>IL6R</i> (rs4537545) and <i>PTPN22</i> (rs2476601)).</p